Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Non-Current Debt: 2023-2025

Historic Non-Current Debt for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $6.7 million.

  • BioLineRx's Non-Current Debt rose 700.00% to $20.0 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $20.0 billion, marking a year-over-year increase of 700.00%. This contributed to the annual value of $5.0 billion for FY2024, which is 100.00% up from last year.
  • Per BioLineRx's latest filing, its Non-Current Debt stood at $6.7 million for Q2 2025, which was down 11.99% from $7.6 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Non-Current Debt registered a high of $18.8 million during Q2 2024, and its lowest value of $5.9 million during Q1 2024.
  • Moreover, its 3-year median value for Non-Current Debt was $8.3 million (2023), whereas its average is $9.8 million.
  • Data for BioLineRx's Non-Current Debt shows a peak YoY soared of 700.00% (in 2025) over the last 5 years.
  • Over the past 3 years, BioLineRx's Non-Current Debt (Quarterly) stood at $2.5 billion in 2023, then soared by 100.00% to $5.0 billion in 2024, then skyrocketed by 700.00% to $20.0 billion in 2025.
  • Its Non-Current Debt stands at $6.7 million for Q2 2025, versus $7.6 million for Q1 2025 and $9.0 million for Q4 2024.